AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35490601 — intervention group
Group type: EXPERIMENTAL
Intervention: eLearning module (n=85)
Number of subjects: 271
Study 35490601 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face teaching (n=186)
Number of subjects: 271
Study 33190991 — intervention group
Group type: EXPERIMENTAL
Intervention: BCM equation for predicting appendicular skeletal muscle mass (ASM)
Number of subjects: 263
Study 33190991 — intervention group
Group type: EXPERIMENTAL
Intervention: BCM equation for predicting ASM
Number of subjects: 263
Study 33590739 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-led care pathway including group education, a splint, and home exercises
Number of subjects: 105
Study 33590739 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 105
Study 33621921 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent intervention
Number of subjects: 2922
Study 33621921 — intervention group
Group type: EXPERIMENTAL
Intervention: Student intervention
Number of subjects: 2922
Study 33621921 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent + Student intervention
Number of subjects: 2922
Study 33621921 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 2922
Study 32033815 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublobar resection (SLR)
Number of subjects: 53973
Study 32033815 — intervention group
Group type: COMPARATOR
Intervention: Stereotactic body radiation therapy (SBRT)
Number of subjects: 53973
Study 32033815 — intervention group
Group type: COMPARATOR
Intervention: Ablation
Number of subjects: 53973
Study 35653338 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg/day
Number of subjects: 523
Study 35653338 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg/day
Number of subjects: 523
Study 35653338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 523
Study 32058451 — intervention group
Group type: EXPERIMENTAL
Intervention: True dry needling
Number of subjects: 62
Study 32058451 — intervention group
Group type: COMPARATOR
Intervention: Sham dry needling
Number of subjects: 62
Study 32780676 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV self-testing
Number of subjects: 24
Study 35279069 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) group
Number of subjects: 508
Study 35279069 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 508
Study 34479057 — intervention group
Group type: EXPERIMENTAL
Intervention: SARA (Scale for the Assessment and Rating of Ataxia)
Number of subjects: 20
Study 34479057 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Global Impression of Change scale
Number of subjects: 20
Study 32410683 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin
Number of subjects: 426
Study 32410683 — intervention group
Group type: COMPARATOR
Intervention: Control (Normal Saline)
Number of subjects: 426
Study 33349043 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard active training instruction
Number of subjects: 33
Study 33349043 — intervention group
Group type: COMPARATOR
Intervention: Placebo-related instruction
Number of subjects: 33
Study 32723107 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram to predict 14-day probability of poor outcome
Number of subjects: 279
Study 32723107 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable analyses
Number of subjects: 279
Study 32723107 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram
Number of subjects: 279
Study 35447274 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive range of motion (PROM) exercise
Number of subjects: 0
Study 35447274 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 32720608 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (1g IV every 12 hours for at least 7 days)
Number of subjects: 59
Study 32720608 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin (750 mg IV daily for at least 7 days)
Number of subjects: 59
Study 32320006 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside (NR) 1000 mg/d for 6 weeks
Number of subjects: 13
Study 32320006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 35962482 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet (MD)
Number of subjects: 23
Study 35962482 — intervention group
Group type: COMPARATOR
Intervention: Low-Fat Diet (LFD)
Number of subjects: 23
Study 33606004 — intervention group
Group type: EXPERIMENTAL
Intervention: D-RVd (daratumumab plus lenalidomide/bortezomib/dexamethasone)
Number of subjects: 16
Study 33606004 — intervention group
Group type: EXPERIMENTAL
Intervention: D-RVd (daratumumab plus lenalidomide/bortezomib/dexamethasone) followed by D-R (daratumumab plus lenalidomide) maintenance
Number of subjects: 16
Study 32698144 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically instrumented TSH (approximately 0.8 mIU/L)
Number of subjects: 451025
Study 36170970 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasted (FAST)
Number of subjects: 16
Study 36170970 — intervention group
Group type: COMPARATOR
Intervention: Fed (FED)
Number of subjects: 16
Study 32703721 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD)
Number of subjects: 80
Study 32703721 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 35701760 — intervention group
Group type: EXPERIMENTAL
Intervention: Family meal
Number of subjects: 32
Study 35701760 — intervention group
Group type: EXPERIMENTAL
Intervention: School meal
Number of subjects: 32
Study 35701760 — intervention group
Group type: EXPERIMENTAL
Intervention: Friend meal
Number of subjects: 32
Study 35918690 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation interventions
Number of subjects: 80
Study 33565893 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray plus oral antidepressant (ESK + oral AD)
Number of subjects: 0
Study 33565893 — intervention group
Group type: COMPARATOR
Intervention: Oral antidepressant plus nasal placebo (oral AD + PBO)
Number of subjects: 0
Study 32646424 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 μg
Number of subjects: 5652
Study 32646424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5652
Study 35954846 — intervention group
Group type: EXPERIMENTAL
Intervention: Resource-strengthening training for parents (Res@t-P)
Number of subjects: 43
Study 33823606 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-therapy sirolimus-eluting and CD34+ antibody-coated Combo stent (DTS)
Number of subjects: 3146
Study 33823606 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting Orsiro stent (SES)
Number of subjects: 3146
Study 33823606 — intervention group
Group type: EXPERIMENTAL
Intervention: Both DTS and SES
Number of subjects: 3146
Study 36178946 — intervention group
Group type: EXPERIMENTAL
Intervention: Real US-guided dry needling with exercise therapy (G1)
Number of subjects: 84
Study 36178946 — intervention group
Group type: COMPARATOR
Intervention: Placebo US-guided dry needling with exercise therapy (G2)
Number of subjects: 84
Study 36178946 — intervention group
Group type: COMPARATOR
Intervention: Exercise therapy solely (G3)
Number of subjects: 84
Study 33694001 — intervention group
Group type: EXPERIMENTAL
Intervention: 90% calf starter concentrate (CSC) + 10% chopped wheat straw (WS) offered from day 21 of age to weaning (WS21)
Number of subjects: 40
Study 33694001 — intervention group
Group type: EXPERIMENTAL
Intervention: 90% calf starter concentrate (CSC) + 10% chopped wheat straw (WS) offered from day 3 of age to weaning (WS3)
Number of subjects: 40
Study 33694001 — intervention group
Group type: EXPERIMENTAL
Intervention: 90% calf starter concentrate (CSC) + 10% chopped wheat straw (WS) offered from day 40 of age to weaning (WS40)
Number of subjects: 40
Study 33694001 — intervention group
Group type: COMPARATOR
Intervention: Control starter without any wheat straw (WS) inclusion until weaning (WS0)
Number of subjects: 40
Study 32169925 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid closed-loop (CL) insulin delivery for 24 months
Number of subjects: 96
Study 32169925 — intervention group
Group type: COMPARATOR
Intervention: Standard multiple daily injections (MDI) therapy for 24 months
Number of subjects: 96
Study 36450940 — intervention group
Group type: EXPERIMENTAL
Intervention: 200-mg testosterone enanthate/wk (TEST)
Number of subjects: 50
Study 36450940 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 50
Study 32881572 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention (details not specified)
Number of subjects: 209
Study 32881572 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-item scale (abbreviated PTGI and BFS)
Number of subjects: 209
Study 32881572 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-item scale (abbreviated PTGI and BFS)
Number of subjects: 209
Study 32881572 — intervention group
Group type: EXPERIMENTAL
Intervention: 11-item scale (abbreviated PTGI and BFS)
Number of subjects: 209
Study 35677761 — intervention group
Group type: EXPERIMENTAL
Intervention: PA + SB group (dyadic approach)
Number of subjects: 150
Study 35677761 — intervention group
Group type: EXPERIMENTAL
Intervention: PA + SB + sleep group (integrated approach)
Number of subjects: 150
Study 35677761 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 150
Study 33241429 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-guided learning using a video-based self-assessment (SA)
Number of subjects: 24
Study 33241429 — intervention group
Group type: COMPARATOR
Intervention: Control group watching an LH video demonstration
Number of subjects: 24
Study 35134151 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation (CBA)
Number of subjects: 101
Study 35134151 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 101
Study 34342246 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% Trypan blue (TB) applied to one eye before capsulorhexis
Number of subjects: 46
Study 34342246 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TB applied)
Number of subjects: 46
Study 35713950 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone 200 mg daily
Number of subjects: 66
Study 35713950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 33428364 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompression, decompression with fusion, and decompression with stabilization
Number of subjects: 70
Study 33428364 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 70
Study 33619014 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of nebulised dornase alfa for one month
Number of subjects: 28
Study 33619014 — intervention group
Group type: COMPARATOR
Intervention: Standard care (no withdrawal of dornase alfa)
Number of subjects: 28
Study 32238338 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of web and text message platforms (on)
Number of subjects: 864
Study 32238338 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic tailoring of intervention content based on user engagement (on)
Number of subjects: 864
Study 32238338 — intervention group
Group type: EXPERIMENTAL
Intervention: All experimental factors active (personalization, integration, dynamic tailoring, message intensity)
Number of subjects: 864
Study 32238338 — intervention group
Group type: EXPERIMENTAL
Intervention: Build Support System
Number of subjects: 864
Study 32238338 — intervention group
Group type: EXPERIMENTAL
Intervention: Choose Quit Smoking Aid
Number of subjects: 864
Study 32238338 — intervention group
Group type: EXPERIMENTAL
Intervention: Track Smoking Triggers
Number of subjects: 864
Study 32238338 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall feature utilization
Number of subjects: 864
Study 32238338 — intervention group
Group type: EXPERIMENTAL
Intervention: Time on site
Number of subjects: 864
Study 34435933 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of tetravalent measles-mumps-rubella-varicella vaccine (V2 group)
Number of subjects: 1000
Study 34435933 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose trivalent measles-mumps-rubella (MMR) vaccine and one dose of varicella vaccine (V1 group)
Number of subjects: 1000
Study 34435933 — intervention group
Group type: COMPARATOR
Intervention: Two doses of MMR vaccine (V0 group, control)
Number of subjects: 1000
Study 34435933 — intervention group
Group type: EXPERIMENTAL
Intervention: Both V2 and V1 groups
Number of subjects: 1000
Study 34435933 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 1000
Study 32686972 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle‐promoting text messages sent every week for six months
Number of subjects: 60
Study 32686972 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 60
Study 36104819 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent and Public Involvement (PPI) process in trial planning
Number of subjects: 675
Study 36104819 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI impact on study design
Number of subjects: 675
Study 34078421 — intervention group
Group type: EXPERIMENTAL
Intervention: gelatine‐crystalloid regime (Gelaspan® 4% and Sterofundin® ISO, B. Braun Melsungen AG, in a 1:1 ratio)
Number of subjects: 608
Study 34078421 — intervention group
Group type: COMPARATOR
Intervention: pure crystalloid regime (Sterofundin® ISO)
Number of subjects: 608
Study 36149254 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis (IVT)
Number of subjects: 13901
Study 36149254 — intervention group
Group type: COMPARATOR
Intervention: Other medical management
Number of subjects: 13901
Study 33579345 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) combined with branched-chain amino acids (BCAA)
Number of subjects: 50
Study 33579345 — intervention group
Group type: COMPARATOR
Intervention: Neuromuscular electrical stimulation (NMES) alone
Number of subjects: 50
Study 33827700 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol treatment (0.25 mcg/day for 4 months)
Number of subjects: 128
Study 33827700 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol treatment (0.25 mcg/day for 4 months) in patients with Ff genotype
Number of subjects: 128
Study 33827700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 34007434 — intervention group
Group type: EXPERIMENTAL
Intervention: Operating room nursing intervention combined with traditional treatment methods
Number of subjects: 80
Study 34007434 — intervention group
Group type: COMPARATOR
Intervention: Traditional nursing combined with traditional treatment
Number of subjects: 80
Study 32003520 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Coach intervention
Number of subjects: 39
Study 34463805 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral analgesia group (spinal fentanyl followed by oral tramadol, paracetamol, and diclofenac every 6 hours for 48 hours)
Number of subjects: 200
Study 34463805 — intervention group
Group type: COMPARATOR
Intervention: Spinal morphine group (spinal morphine followed by oral tramadol, paracetamol, and diclofenac)
Number of subjects: 200
Study 33020005 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 educational sessions, parent feedback via the Communication Assessment Tool (CAT), monthly communication tips
Number of subjects: 36
Study 33020005 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 35409693 — intervention group
Group type: EXPERIMENTAL
Intervention: BCLT program (n = 47)
Number of subjects: 93
Study 35409693 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 46)
Number of subjects: 93
Study 32048017 — intervention group
Group type: EXPERIMENTAL
Intervention: UHMWPE‐XE
Number of subjects: 94
Study 32048017 — intervention group
Group type: COMPARATOR
Intervention: UHMWPE‐X
Number of subjects: 94
Study 32048017 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 94
Study 34856706 — intervention group
Group type: EXPERIMENTAL
Intervention: SNK01 plus pembrolizumab
Number of subjects: 18
Study 34856706 — intervention group
Group type: COMPARATOR
Intervention: pembrolizumab monotherapy
Number of subjects: 18
Study 33492879 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure applied to the Neiguan (PC 6) acupuncture point
Number of subjects: 91
Study 33492879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 35286760 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept-based immunosuppression (Tacrolimus, Belatacept, and prednisone until day 89 followed by Belatacept, Mycophenolate Mofetil, and prednisone)
Number of subjects: 27
Study 35286760 — intervention group
Group type: COMPARATOR
Intervention: Control (Tacrolimus, Mycophenolate Mofetil, and prednisone)
Number of subjects: 27
Study 35286760 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept-based immunosuppression
Number of subjects: 27
Study 35286760 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 27
Study 34197699 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led medication therapy monitoring and management via a smartphone-enabled mHealth app
Number of subjects: 0
Study 34197699 — intervention group
Group type: COMPARATOR
Intervention: Usual posttransplant care (Control)
Number of subjects: 0
Study 34197699 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention
Number of subjects: 0
Study 34821175 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy (cisplatin with pemetrexed)
Number of subjects: 66
Study 34821175 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus chemotherapy (cisplatin with pemetrexed)
Number of subjects: 66
Study 32799960 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic mucosal disease group
Number of subjects: 67
Study 32799960 — intervention group
Group type: COMPARATOR
Intervention: Chronic squamous disease group
Number of subjects: 67
Study 616411671 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosimilar CT-P13
Number of subjects: 0
Study 616411671 — intervention group
Group type: COMPARATOR
Intervention: Originator infliximab
Number of subjects: 0
Study 36420937 — intervention group
Group type: EXPERIMENTAL
Intervention: PFMT + EA
Number of subjects: 304
Study 36420937 — intervention group
Group type: COMPARATOR
Intervention: PFMT + sham EA
Number of subjects: 304
Study 34895064 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive-Behavioral Sex Therapy (MBCST)
Number of subjects: 70
Study 34895064 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study 35817672 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin (1 mg/kg bolus followed by 2.5 mg/kg/h infusion, adjusted to maintain ACT >480 s)
Number of subjects: 25
Study 35817672 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin (1 mg/kg bolus followed by 2.2 ± 0.4 mg/kg/h infusion)
Number of subjects: 25
Study 35817672 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 25
Study 34593526 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR)
Number of subjects: 89
Study 35272050 — intervention group
Group type: EXPERIMENTAL
Intervention: Contoured foot orthoses
Number of subjects: 88
Study 35272050 — intervention group
Group type: COMPARATOR
Intervention: Sham flat insoles
Number of subjects: 88
Study 32151792 — intervention group
Group type: EXPERIMENTAL
Intervention: Illusory patterns with vertically aligned white dots in T shape
Number of subjects: 0
Study 32151792 — intervention group
Group type: EXPERIMENTAL
Intervention: Illusory patterns with vertically aligned white dots in L shape
Number of subjects: 0
Study 32151792 — intervention group
Group type: COMPARATOR
Intervention: Comparison of T shape vs L shape configurations
Number of subjects: 0
Study 33883508 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine adsorption (CytoSorb)
Number of subjects: 46
Study 33883508 — intervention group
Group type: COMPARATOR
Intervention: Control (no cytokine adsorption)
Number of subjects: 46
Study 32428786 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training, nutritional education, and medication reconciliation for 5.1 ± 0.6 months
Number of subjects: 391
Study 35616942 — intervention group
Group type: EXPERIMENTAL
Intervention: Spermidine supplementation (0.9 mg spermidine/d) for 12 months
Number of subjects: 100
Study 35616942 — intervention group
Group type: COMPARATOR
Intervention: Placebo (microcrystalline cellulose) for 12 months
Number of subjects: 100
Study 33564824 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (800 µg daily for 3 years)
Number of subjects: 791
Study 35277080 — intervention group
Group type: EXPERIMENTAL
Intervention: Potato dishes (POT)
Number of subjects: 50
Study 35277080 — intervention group
Group type: COMPARATOR
Intervention: Refined grain dishes (REF)
Number of subjects: 50
Study 32857212 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated ASPECTS software
Number of subjects: 459
Study 32857212 — intervention group
Group type: COMPARATOR
Intervention: Observers
Number of subjects: 459
Study 32748994 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient evaluation
Number of subjects: 2060
Study 32748994 — intervention group
Group type: COMPARATOR
Intervention: Outpatient testing (early emergency room discharge)
Number of subjects: 2060
Study 35173154 — intervention group
Group type: EXPERIMENTAL
Intervention: penicillin + gentamicin
Number of subjects: 147
Study 35173154 — intervention group
Group type: EXPERIMENTAL
Intervention: co-amoxiclav + gentamicin
Number of subjects: 147
Study 35173154 — intervention group
Group type: EXPERIMENTAL
Intervention: amoxicillin + cefotaxime
Number of subjects: 147
Study 35173154 — intervention group
Group type: COMPARATOR
Intervention: non-antibiotic treated infants (control group)
Number of subjects: 147
Study 35868622 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary IOL implantation
Number of subjects: 43
Study 35868622 — intervention group
Group type: EXPERIMENTAL
Intervention: Measured anterior chamber depth (ACD) used to calculate predicted refraction
Number of subjects: 43
Study 35868622 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple regression analysis
Number of subjects: 43
Study 34480008 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate (SB; 0.3 g/kg body mass) with HI warm-up
Number of subjects: 12
Study 34480008 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate (SB; 0.3 g/kg body mass) with LI warm-up
Number of subjects: 12